Figure 1. Challenges for adoptive T-cell therapy and proposed gene transfer and genome-editing solutions. Several challenges need to be faced to fully exploit the ability of T lymphocytes to eradicate cancer cells. Several of these challenges can be addressed by gene transfer (gene addition) and... More about this image found in Challenges for adoptive T-cell therapy and proposed gene transfer and genom...

Figure 2. Timeline of adoptive T-cell therapy with engineered T cells. This figure represents a timeline of some of the key milestones in adoptive T-cell therapy with engineered cells for cancer treatment. ADA SCID, adenosine deaminase severe combined immunodeficiency; allo-HSCT, allogeneic hema... More about this image found in Timeline of adoptive T-cell therapy with engineered T cells. This figure r...

Figure 3. TCRs and CARs. This picture depicts the advantages (green arrow) and disadvantages (red arrow) of chimeric antigen receptors (CARs) and T-cell receptors (TCRs) for adoptive T-cell therapy for cancer. HLA, human leukocyte antigen. More about this image found in TCRs and CARs. This picture depicts the advantages (green arrow) and disad...

Figure 4. Genome-editing tools: mode of action. Several genome-editing tools, with different characteristics and modes of action, have been developed and tested for their efficiency in engineering the genome of mammalian cells, including T lymphocytes. While zinc finger nucleases, TALEN, and CRI... More about this image found in Genome-editing tools: mode of action. Several genome-editing tools, with d...

Figure 5. Manufacturing disease-specific engineered T-cell–based cellular products. Based on disease diagnosis, antigen repertoire, and knowledge of the characteristics of the tumor microenvironment, different biotechnological reagents can be combined to generate T-cell–based cellular products w... More about this image found in Manufacturing disease-specific engineered T-cell–based cellular products. ...